One Loss, One Tie: US FDA Panels Prove Difficult For Opioid Sponsors Intellipharmaceutics, Esteve

 
• By Sue Sutter
FDA Advisory Committee Feature image
A US FDA panel overwhelmingly rejected one opioid formulation but delivered a split verdict on another.

More from US FDA Performance Tracker

More from Regulatory Trackers